KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
This study is testing an experimental cell therapy called KYV-101 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if this new treatment works better than the usual medical care currently used for this disease.
You might be able to join if you are an adult with confirmed muscle weakness from myasthenia gravis whose symptoms have not improved enough after trying multiple standard treatments. There are also health and safety guidelines, such as not having certain other neurological conditions or major organ diseases.
Participants will be randomly chosen to either receive the new KYV-101 cell therapy, which includes a preparation treatment to clear out certain white blood cells first, or to continue with their ongoing standard-of-care immunosuppressive therapy. Your health team will monitor you closely throughout the process to ensure your safety.
The study is currently active and recruiting participants at multiple medical locations in California, United States.
- 1Testing an advanced cell therapy called KYV-101 against standard medical care.
- 2Designed for patients whose myasthenia gravis symptoms are not well controlled by current treatments.
- 3Currently recruiting patients at study sites in California.
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.